Key HIV Studies Influencing My Practice Following CROI 2022—Audio Recap

In this episode, Daniel R. Kuritzkes, MD, and David A. Wohl, MD, discuss new HIV data from CROI 2022, including:

• Prevention strategies
  • Data on long-acting (LA) cabotegravir for pre-exposure prophylaxis from an additional 1-year unblinded period of HPTN 083
  • Data on the use of a single genome assay for integrase resistance showing that a sensitive HIV-1 RNA assay would have detected infection before integrase strand transfer inhibitor resistance developed in most patients in HPTN 083
  • Metabolic and renal outcomes with islatravir for pre-exposure prophylaxis in the MK8591-016 trial
  • Efficacy of an HIV-1 vaccine regimen in African women in the Imbokodo study
• LA therapies
  • CALIBRATE study of lenacapavir in treatment-naive patients
  • CAPELLA study of lenacapavir in heavily treatment–experienced patients
  • Efficacy and safety of LA cabotegravir plus rilpivirine every 8 weeks vs every 4 weeks in ATLAS-2M
• Second-line therapies
  • The VISEND study comparing dolutegravir-based antiretroviral therapy (ART) vs protease inhibitor–basedART for second-line therapy
  • The NADIA study comparing dolutegravir withdarunavir/ritonavir and tenofovir disoproxil fumarate with zidovudine for second-line therapy
• Comorbidities and cure
  • ACTG A5324 (InMIND) study of ART intensification for cognitive impairment in people with HIV
  • IMPAACT P1107 case of patient with loss of HIV-1–specific antibody response and viral detection following CCR5∆32/∆32 cord/haploidentical transplant